Reuters logo
BRIEF-China FDA approves ctas for Beyondspring's second global plinabulin registrational trial
July 6, 2017 / 12:22 PM / 3 months ago

BRIEF-China FDA approves ctas for Beyondspring's second global plinabulin registrational trial

July 6 (Reuters) - Beyondspring Inc:

* China FDA approves ctas for beyondspring’s second global plinabulin registrational trial for chemotherapy-induced neutropenia prevention

* Beyondspring- approved company’s clinical trial applications (ctas) to allow initiation of two global phase 2/3 trials for its lead asset, plinabulin

* Beyondspring-Targeting reporting phase 2 efficacy data in 2h 2017, phase 3 interim data in 2018, submitting NDA in 2019 to FDA and CFDA for plinabulin Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below